MDR1 mRNA expression and MDR1 gene variants as predictors of response to chemotherapy in patients with acute myeloid leukaemia: A meta-analysis

Biomarkers

Volumn 18, Issue 5, 2013, Pages 425-435

  Doxani, Chrysoula ^a,b   Voulgarelis, Michael ^b   Zintzaras, Elias ^a,c  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AML; Chemotherapy; Expression; Gene; Leukemia; MDR1; Meta analysis; Response

Indexed keywords

ANTHRACYCLINE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; GENETIC MODEL; GENETIC VARIABILITY; HUMAN; META ANALYSIS; PHARMACOGENOMICS; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENETIC ASSOCIATION STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84880531524     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.808263     Document Type: Article

References (53)

1. Burnett A, Wetzler M, Löwenberg B. (2011). Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29:487-94.
2. Cascorbi I. (2011). P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 201:261-83.
3. Chauhan PS, Bhushan B, Singh LC, et al. (2012). Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy. Exp Mol Pathol 92:44-9.
4. Cheson B, Bennett J, Kopecky K, et al. (2003). Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21: 4642-9.
5. Cochran WG. (1954). Some methods for strengthening the common-2 tests. Biometrics 10:417-51.
6. Dahl GV, Lacayo NJ, Brophy N, et al. (2000). Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. J Clin Oncol 18:1867-75.
7. de Lima M, Strom S, Keating M, et al. (1997). Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood 90:4719-24.
8. DerSimonian R, Laird N. (1986). Meta-analysis in clinical trials. Control Clin Trials 7:177-88.
9. Estey EH. (2002). Treatment of acute myelogenous leukemia. Oncology 16:343-52.
10. Estey E, Döhner H. (2006). Acute myeloid leukaemia. Lancet 368: 1894-907.
11. Fujimaki S, Funato T, Harigae H, et al. (2002). Quantitative analysis of a MDR1 transcript for prediction of drug resistance in acute leukemia. Clin Chem 48:811-17.
12. Gottesman MM, Fojo T, Bates SE. (2002). Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2:48-58.
13. Gruber A, Vitols S, Norgren S, et al. (1992). Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia. Br J Cancer 66:266-72.
14. Gsur A, Zöchbauer S, Götzl M, et al. (1993). MDR1 RNA expression as a prognostic factor in acute myeloid leukemia: an update. Leuk Lymphoma 12:91-4.
15. Guenova ML, Balatzenko GN, Nikolova VR, et al. (2010). An antiapoptotic pattern correlates with multidrug resistance in acute myeloid leukemia patients: a comparative study of active caspase-3, cleaved PARPs, Bcl-2, Survivin and MDR1 gene. Hematology 15:135-43.
16. Harbord RM, Egger M, Sterne JA. (2006). A modified test for smallstudy effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25:3443-57.
17. Hart SM, Ganeshaguru K, Scheper RJ, et al. (1997). Expression of the human major vault protein LRP in acute myeloid leukemia. Exp Hematol 25:1227-32.
18. Hartmann G, Kim H, Piquette-Miller M. (2001). Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines inmice. Int Immunopharmacol 1:189-99.
19. Hedges LV, Olkin I. (1985). Statistical methods for meta-analysis. Orlando: Academic Press.
20. Higgins JP, Thompson SG. (2002). Quantifying heterogeneity in a metaanalysis. Stat Med 21:1539-58.
21. Ho MM, Hogge DE, Ling V. (2008). MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Exp Hematol 36:433-42.
22. Howlader N, Noone AM, Krapcho M, et al. (2011). SEER cancer statistics review, 1975-2008. Bethesda (MD): National Cancer Institute.
23. Huang Y. (2007). Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev 26:183-201.
24. Huh HJ, Park CJ, Jang S, et al. (2006). Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia. J Korean Med Sci 21:253-8.
25. Hunault M, Zhou D, Delmer A, et al. (1997). Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment. Ann Hematol 74: 65-71.
26. Hur EH, Lee JH, Lee MJ, et al. (2008). C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia. Leuk Res 32:1601-4.
27. Illmer T, Schuler US, Thiede C, et al. (2002). MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62:4955-62.
28. Kim DH, Park JY, Sohn SK,et al. (2006). Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer 118:2195-201.
29. Kitsios GD, Zintzaras E. (2009). Genomic convergence of genome-wide investigations for complex traits. Ann Hum Genet 73:514-19.
30. Leith CP, Kopecky KJ, Chen IM, et al. (1999). Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94:1086-99.
31. Lin SF, Huang SM, Chen TP, et al. (1995). MDR1 gene expression in acute myeloid leukemia: clinical correlation. J Formos Med Assoc 94: 111-16.
32. Monzo M, Brunet S, Urbano-Ispizua A, et al. (2006). Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 107:4871-9.
33. Petti MC, Tafuri A, Latagliata R, et al. (2003). High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias. Ann Hematol 82: 476-80.
34. Sato H, Preisler H, Day R, et al. (1990). MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol 75:340-5.
35. Schaich M, Harbich-Brutscher E, Pascheberg U, et al. (2002). Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome. Haematologica 87:455-64.
36. Tallman MS, Gilliland DG, Rowe JM. (2005). Drug therapy of acute myeloid leukemia. Blood 106:1154-63.
37. Tan Y, Li G, Zhao C, et al. (2003). Expression of sorcin predicts poor outcome in acute myeloid leukemia. Leuk Res 27:125-31.
38. Trikalinos TA, Salanti G, Zintzaras E, Ioannidis JP. (2008). Metaanalysis methods. Adv Genet 60:311-34.
39. Trnková Z, Bedrl?́ková R, Marková J, et al. (2007). Semiquantitative RT-PCR evaluation of the MDR1 gene expression in patients with acute myeloid leukemia. Neoplasma 54:383-90.
40. Van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, et al. (2007). CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol 86:329-37.
41. Van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH, et al. (2006). ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther 80:427-39.
42. Venditti A, Del Poeta G, Maurillo L, et al. (2004). Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia. Haematologica 89:934-9.
43. Verhaak RG, Valk PJ. (2010). Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia. Cancer Treat Res 145:67-83.
44. Wells RJ, Odom LF, Gold SH, et al. (1994). Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1. Med Pediatr Oncol 22:244-9.
45. Whitehead A. (2002). Meta-analysis of controlled clinical trials. Chichester, UK: John Wiley & Sons, Ltd.
46. Xu D, Areström I, Virtala R, et al. (1999). High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone. Br J Haematol 106:627-33.
47. Zintzaras E. (2010). The generalized odds ratio as a measure of genetic risk effect in the analysis and meta-analysis of association studies. Stat Appl Genet Mol Biol 9: Article 21.
48. Zintzaras E. (2012). The power of generalized odds ratio in assessing association in genetic studies with known mode of inheritance. J Appl Stat 39:2569-81.
49. Zintzaras E, Ioannidis JP. (2005). Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28:123-37.
50. Zintzaras E, Lau J. (2008a). Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol 61: 634-45.
51. Zintzaras E, Lau J. (2008b). Trends in meta-analysis of genetic association studies. J Hum Genet 53:1-9.
52. Zintzaras E, Kitsios GD. (2009). Synopsis and synthesis of candidate-gene association studies in chronic lymphocytic leukemia: the CUMAGAS-CLL information system. Am J Epidemiol 170: 671-8.
53. Zintzaras E, Doxani C, Ziogas DC, et al. (2011). Bone mineral density and genetic markers involved in three connected pathways (focal adhesion, actin cytoskeleton regulation and cell cycle): the CUMAGAS-BMD information system. Biomarkers 16:698-708.